Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of venous versus bloodspot infliximab level testing in pediatric inflammatory bowel disease
NL-OMON45579Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Erasmus MC. Primary endpoints: Comparison of venous and bloodspot infliximab levels and Comparison of venous and bloodspot anti-drug antibodies. Started Oct 2017; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON45579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45579.